A5083342021- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Glycosylation and Glycoproteins Research
- T-cell and B-cell Immunology
- Vascular Malformations Diagnosis and Treatment
- Intracranial Aneurysms: Treatment and Complications
- Radiopharmaceutical Chemistry and Applications
- Virus-based gene therapy research
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Viral-associated cancers and disorders
- Cutaneous lymphoproliferative disorders research
- Radiation Therapy and Dosimetry
- Cell Adhesion Molecules Research
- Immunodeficiency and Autoimmune Disorders
- Viral Infectious Diseases and Gene Expression in Insects
- Single-cell and spatial transcriptomics
- Meningioma and schwannoma management
- Advanced Radiotherapy Techniques
- vaccines and immunoinformatics approaches
Stanford University
2016-2025
Weizmann Institute of Science
1977-2025
Palo Alto University
1966-2024
Temple University
2023-2024
Kingston General Hospital
2024
Queens University
2024
Queen's University
2024
Musgrove Park Hospital
2023
Hôpital Necker-Enfants Malades
2023
The University of Texas MD Anderson Cancer Center
1999-2023
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.In this multicenter, 2 we enrolled 111 diffuse lymphoma, primary mediastinal or transformed follicular who had disease despite undergoing recommended prior therapy. Patients received target dose 2×106 CAR T cells per kilogram body weight receiving conditioning...
PURPOSE The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody effectively mediates host effector functions and itself less immunogenic are murine antibodies. PATIENTS AND METHODS This was a multiinstitutional trial the anti-CD20 antibody, IDEC-C2B8. Patients with relapsed low grade follicular lymphoma received an outpatient treatment course IDEC-C2B8 375 mg/m2 intravenously...
Purpose: Although rituximab is now routinely used in the treatment of B-cell non-Hodgkin’s lymphoma, mechanism its antitumor effect not clear. One potential action involves antibody-dependent cellular cytotoxicity (ADCC). Two aspects ADCC influence effectiveness this process: susceptibility tumor cells and activation effector via their immunoglobulin G fragment C receptors (FcγRs). Several FcγR polymorphisms have been identified that may affect killing function natural killer macrophages....
Abstract Evidence is presented for two populations of Ia-like molecules on the human B cell line Raji. Two monoclonal antibodies, L203 and L227, are described. Both recognize nonpolymorphic determinants antigens. immunoprecipitate 34,000- 28,000-dalton material from 125I-labeled extracts Raji, but L227 precipitates 25,000-dalton as well. Immunodepletion experiments confirm that antibodies react with different molecules.
HUMAN B-cell malignant tumors result from the proliferation of single clones cells that express surface markers characteristic normal B lymphocytes.1 , 2 In particular, immunoglobulin expressed by these is monoclonal — i.e., restricted to a light-chain type and particular variable region unique each case. The (idiotype) lymphoma clone may be considered tumor-specific marker, distinguishing tumor in patient. We others have shown anti-idiotype antibodies can used monitor investigate biology...
Several gene-expression signatures can be used to predict the prognosis in diffuse large-B-cell lymphoma, but lack of practical tests for a genome-scale analysis has restricted use this method.We studied 36 genes whose expression had been reported survival lymphoma. We measured each these independent samples lymphoma from 66 patients by quantitative real-time polymerase-chain-reaction analyses and related results overall survival.In univariate analysis, were ranked on basis their ability...
PURPOSE: This phase II trial investigated the safety and efficacy of re-treatment with rituximab, a chimeric anti-CD20 monoclonal antibody, in patients low-grade or follicular non-Hodgkin’s lymphoma who relapsed after response to rituximab therapy. PATIENTS AND METHODS: Fifty-eight were enrolled onto this study, two re-treated within study. Patients received an intravenous infusion 375 mg/m 2 weekly for 4 weeks. All had at least prior therapies one course median interval 14.5 months between...
PURPOSE To evaluate the safety, pharmacokinetics, and biologic effect of multiple doses chimeric anti-CD20 monoclonal antibody (mAb) IDEC-C2B8 in patients with relapsed B-cell lymphoma. PATIENTS AND METHODS Twenty low-grade (n = 15) or intermediate-/high-grade 5) lymphoma received weekly infusions times four 125 mg/m2 3), 250 7), 375 10) IDEC-C2B8. RESULTS Infusional side effects during initial infusion were mainly grade I/II fever, asthenia, chills, nausea, rash, urticaria. More serious...
The idiotypic determinants of the surface immunoglobulin a B-cell lymphoma can serve as clonal tumor-specific marker, which may have implications for immunotherapy. We sought to determine whether idiotype-specific immune responses against this autologous antigen could be induced in patients with lymphoma.
Combining tumor antigens with an immunostimulant can induce the immune system to specifically eliminate cancer cells. Generally, this combination is accomplished in ex vivo, customized manner. In a preclinical lymphoma model, intratumoral injection of Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors.We treated 15 patients low-grade B-cell using low-dose radiotherapy single site and-at that same site-injected C-G enriched, synthetic...
Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor behavior and outcomes, yet the identification of poor-risk groups remains challenging. In addition, biology underlying these differences is incompletely understood. We hypothesized that characterization mutational heterogeneity genomic evolution using circulating DNA (ctDNA) profiling could reveal molecular determinants adverse outcomes. To address this hypothesis, we applied cancer personalized by deep...
Significance Antibodies that block the negative signals between PD1-Ligand on tumor cells and PD-1 T are effective therapies against several types of cancer. Ibrutinib, a covalent inhibitor BTK is an approved therapy for B-cell leukemia lymphoma. But ibrutinib also inactivates ITK, enzyme required certain subsets lymphocytes (Th2 cells). We found combination anti–PD-L1 antibodies led to impressive therapeutic effects not only in animal models lymphoma but, surprisingly, breast cancer colon...